TMCnet News
Kane Biotech Obtains ISO 13485 CertificationWINNIPEG, Manitoba, May 18, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today that it has obtained ISO 13485:2016 certification for its quality management system specific to its ongoing efforts to design and develop novel medical devices for the wound care market. “Quality and continuous improvement are core values of Kane and of paramount importance to us,” stated Lori Christofalos, Vice President of Quality & Compliance at Kane Biotech. “Our quality management policies, procedures, and practices have been established to demonstrate our commitment to this high standard and to support future global medical device registrations and approvals. It represents another big step as we continue to drive towards commercialization with our wound care portfolio.” ISO certification demonstrates Kane Biotech’s compliance, and customers can be assured that the medical devices designed and developed are fit for their intended purpose. The process of achieving ISO certification included establishing a quality management system and independent audit to verify conformance through review of the records to the standards. Watch Kane’s latest 2022 wound and surgical care update video here. About ISO ISO is an independent, non-governmental international organization with a membership of 167 national standards bodies. Through its members, it brings together experts to share knowledge and develop voluntary, consensus-based, market relevant International Standards that support innovation and provide solutions to global challenges. About Kane Biotech Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (81 patents and patents pending, trade secrets and trademarks) and products developed by the Compny's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Caution Regarding Forward-Looking Information |